OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Abida on Choosing Between Chemotherapy and Targeted Agents for Patients With Prostate Cancer

November 24th 2016

Wassim Abida, MD, PhD, assistant member and assistant attending physician in the Genitourinary Oncology Program at Memorial Sloan Kettering Cancer Center, discusses treatment options for patients with prostate cancer.

Dr. Oh on the Role of Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

November 23rd 2016

William K. Oh, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses the role of docetaxel in the treatment of patients with metastatic hormone-sensitive prostate cancer.

Dr. Levine on Recent Progress in Cervical Cancer

November 23rd 2016

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses the recent strides made in the treatment of patients with cervical cancer.

Dr. Carey on QOL Changes Seen in Patients With Breast Cancer

November 23rd 2016

Lisa Carey, MD, associate director, Clinical Research, UNC Lineberger Comprehensive Cancer Center, Richardson and Marilyn Jacobs Preyer Distinguished Professorship for Breast Cancer Research, UNC-Chapel Hill, discusses how she has seen various agents impact quality of life (QOL) when used to treat patients with breast cancer.

Dr. Kumar on Future Treatment Landscape of Multiple Myeloma

November 23rd 2016

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses his vision for the future treatment landscape of multiple myeloma.

Dr. Jasgit Sachdev on What's on the Horizon for Ovarian Cancer

November 23rd 2016

Jasgit Sachdev, MD, clinical associate professor at Translational Genomics Research Institute, discusses the goals she would like to see achieved regarding the treatment of ovarian cancer.

Dr. John L. Marshall on Y-90 in Colorectal Cancer

November 23rd 2016

John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, and director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, discusses Y-90 in metastatic castration resistant colorectal cancer (mCRC).

Dr. Muggia on Combination Treatments in Ovarian Cancer

November 23rd 2016

Franco M. Muggia, MD, professor, Department of Medicine, NYU Langone Medical Center, discusses combination treatments currently being tested for the treatment of patients with ovarian cancer.

Dr. Osarogiagbon on Improving Lung Cancer Cure Rates

November 23rd 2016

Raymond U. Osarogiagbon, MD, FACP, Boston Baskin Cancer Foundation, Baptist Memorial Medical Group, discusses treating patients with lung cancer that have the potential to be cured.

Dr. Vokes on the Treatment Landscape of Recurrent Head and Neck Cancer

November 23rd 2016

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses the treatment landscape of recurrent head and neck cancer.

Dr. Marcom on Impact of FALCON Trial on HR+ Breast Cancer

November 22nd 2016

Paul Kelly Marcom, MD, associate professor of Medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the impact that the FALCON trial findings have had on the field of hormone receptor-positive breast cancer.

Dr. Santos on Exciting Advancements in Field of Lung Cancer

November 22nd 2016

Edgardo S. Santos, MD, medical oncology, internal medicine, Boca Raton Regional Hospital, discusses exciting advancements in the field of lung cancer. Santos shared this insight during the 2016 OncLive State of the Science Summit on Lung Cancer.

Dr. Fonseca on FDA Approval of Daratumumab Triplets in Multiple Myeloma

November 22nd 2016

Rafael Fonseca, MD, professor of Medicine, Mayo Clinic, discuses the recent FDA approval of daratumumab (Darzalex) in combination with lenalidomide and dexamethasone or bortezomib (Velcade) and dexamethasone for patients with relapsed multiple myeloma following at least 1 prior therapy.

Dr. Shlomo Koyfman on Radiation in Recurrent Head and Neck Cancer

November 22nd 2016

Shlomo Koyfman, MD, associate staff, radiation oncology, Cleveland Clinic, discusses radiation therapy in recurrent head and neck cancer.

Dr. Moreau on Combination Treatments in Multiple Myeloma

November 22nd 2016

Philippe Moreau, MD, head of the Hematology Department, University Hospital of Nantes, France, discusses the combination treatments being used to treat patients with multiple myeloma.

Dr. Bekaii-Saab Compares Toxicities of Regorafenib and TAS-102 in Colorectal Cancer

November 22nd 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, compares the toxicity profiles of regorafenib and TAS-102, which are both used to treat patients with metastatic colorectal cancer.

Dr. Robert Dreicer on Overcoming Resistance Pathways in mCRPC

November 21st 2016

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses next-generation antiandrogen therapies in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Tripathy on Immunotherapy Potential in HER2-Positive Breast Cancer

November 19th 2016

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the potential role of immunotherapy in the treatment of patients with HER2-positive breast cancer.

Dr. Stein on Circulating Biomarkers in Prostate Cancer

November 19th 2016

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses the use of novel circulating biomarkers in the treatment of patients with prostate cancer.

Dr. Morris on Novel Approaches With Radium-223 in mCRPC

November 18th 2016

Michael J. Morris, MD, an associate professor of Medicine at Memorial Sloan Kettering Cancer, discusses what novel combinatorial approaches researchers will be explored with radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).